Your browser doesn't support javascript.
loading
Development of an optimized and generic cost-utility model for analyzing genome-guided treatment data.
Pandi, Maria-Theodora; Koromina, Maria; Vonitsanos, Gerasimos; van der Spek, Peter J; Patrinos, George P; Mitropoulou, Christina.
Afiliación
  • Pandi MT; Erasmus University Medical Center Rotterdam, Faculty of Medicine and Health Sciences, Department of Pathology, Clinical Bioinformatics Unit, Rotterdam, The Netherlands.
  • Koromina M; University of Patras, School of Health Sciences, Department of Pharmacy, Patras, Greece.
  • Vonitsanos G; The Golden Helix Foundation, London, UK.
  • van der Spek PJ; Erasmus University Medical Center Rotterdam, Faculty of Medicine and Health Sciences, Department of Pathology, Clinical Bioinformatics Unit, Rotterdam, The Netherlands.
  • Patrinos GP; Erasmus University Medical Center Rotterdam, Faculty of Medicine and Health Sciences, Department of Pathology, Clinical Bioinformatics Unit, Rotterdam, The Netherlands; University of Patras, School of Health Sciences, Department of Pharmacy, Patras, Greece; United Arab Emirates University, College o
  • Mitropoulou C; The Golden Helix Foundation, London, UK. Electronic address: c.mitropoulou@goldenhelix.org.
Pharmacol Res ; 178: 106187, 2022 04.
Article en En | MEDLINE | ID: mdl-35331864
Economic evaluation is an integral component of informed public health decision-making in personalized medicine. However, performing economic evaluation assessments often requires specialized knowledge, expertise, and significant resources. To this end, developing generic models can significantly assist towards providing the necessary evidence for the cost-effectiveness of genome-guided therapeutic interventions, compared to the traditional drug treatment modalities. Here, we report a generic cost-utility analysis model, developed in R, which encompasses essential economic evaluation steps. Specifically, critical steps towards a comprehensive deterministic and probabilistic sensitivity analysis were incorporated in our model, while also providing an easy-to-use graphical user interface, which allows even non-experts in the field to produce a fully comprehensive cost-utility analysis report. To further demonstrate the model's reproducibility, two sets of data were assessed, one stemming from in-house clinical data and one based on previously published data. By implementing the generic model presented herein, we show that the model produces results in complete concordance with the traditionally performed cost-utility analysis for both datasets. Overall, this work demonstrates the potential of generic models to provide useful economic evidence for personalized medicine interventions.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Reproducibilidad de los Resultados Tipo de estudio: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Pharmacol Res Asunto de la revista: FARMACOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Reproducibilidad de los Resultados Tipo de estudio: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Pharmacol Res Asunto de la revista: FARMACOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Países Bajos